US6225289B1
(en)
|
1998-12-10 |
2001-05-01 |
Genvec, Inc. |
Methods and compositions for preserving adenoviral vectors
|
WO2000050075A2
(en)
*
|
1999-02-26 |
2000-08-31 |
Chiron S.P.A. |
Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs
|
US6558670B1
(en)
|
1999-04-19 |
2003-05-06 |
Smithkline Beechman Biologicals S.A. |
Vaccine adjuvants
|
EP2322210A1
(en)
|
1999-04-19 |
2011-05-18 |
GlaxoSmithKline Biologicals S.A. |
Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
|
KR100863367B1
(ko)
*
|
1999-05-13 |
2008-10-13 |
와이어쓰 홀딩스 코포레이션 |
보조제 배합 제형물
|
GB9921146D0
(en)
*
|
1999-09-07 |
1999-11-10 |
Smithkline Beecham Biolog |
Novel composition
|
DE60038971D1
(de)
|
1999-10-22 |
2008-07-03 |
Aventis Pasteur |
Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
|
EP1282702B1
(en)
|
2000-05-10 |
2006-11-29 |
Sanofi Pasteur Limited |
Immunogenic polypeptides encoded by mage minigenes and uses thereof
|
PL211151B1
(pl)
|
2000-10-18 |
2012-04-30 |
Glaxosmithkline Biolog Sa |
Kompozycja immunogenna oraz zastosowanie połączenia saponiny, oligonukleotydu immunostymulującego i lipopolisacharydu
|
TWI228420B
(en)
*
|
2001-05-30 |
2005-03-01 |
Smithkline Beecham Pharma Gmbh |
Novel vaccine composition
|
CN1555253A
(zh)
*
|
2001-09-13 |
2004-12-15 |
������ѧ�����о�Ժ |
化疗栓塞用紫杉醇的油性组合物、制剂及它们的制造方法
|
EP1547607A4
(en)
*
|
2002-08-02 |
2008-11-26 |
Dainippon Sumitomo Pharma Co |
PREPARATION OF A COMPONENT OF BACTERIA CELL WALL SKELETON
|
CA2502268A1
(en)
|
2002-10-23 |
2004-05-06 |
Glaxosmithkline Biologicals S.A. |
Methods for vaccinating against malaria
|
GB0411411D0
(en)
*
|
2004-05-21 |
2004-06-23 |
Glaxosmithkline Biolog Sa |
Vaccines
|
DE602005025342D1
(de)
|
2004-05-28 |
2011-01-27 |
Glaxosmithkline Biolog Sa |
Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
|
GB0417494D0
(en)
|
2004-08-05 |
2004-09-08 |
Glaxosmithkline Biolog Sa |
Vaccine
|
CA2603180C
(en)
|
2005-03-23 |
2015-10-13 |
Glaxosmithkline Biologicals S.A. |
Influenza vaccine compositions and method for immunization against influenza disease
|
GB0513421D0
(en)
|
2005-06-30 |
2005-08-03 |
Glaxosmithkline Biolog Sa |
Vaccines
|
US11707520B2
(en)
|
2005-11-03 |
2023-07-25 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
PL1945252T3
(pl)
*
|
2005-11-04 |
2013-11-29 |
Seqirus Uk Ltd |
Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
|
GB0522765D0
(en)
|
2005-11-08 |
2005-12-14 |
Chiron Srl |
Combination vaccine manufacture
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
AR058592A1
(es)
|
2005-12-22 |
2008-02-13 |
Glaxosmithkline Biolog Sa |
Vacuna
|
KR101541383B1
(ko)
|
2006-03-30 |
2015-08-03 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
면역원성 조성물
|
US9839685B2
(en)
|
2006-04-13 |
2017-12-12 |
The Regents Of The University Of Michigan |
Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
|
US10138279B2
(en)
|
2006-04-13 |
2018-11-27 |
Regents Of The University Of Michigan |
Compositions and methods for Bacillus anthracis vaccination
|
JP5639760B2
(ja)
|
2006-07-17 |
2014-12-10 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
インフルエンザワクチン
|
ES2525732T3
(es)
|
2006-07-18 |
2014-12-29 |
Glaxosmithkline Biologicals S.A. |
Vacunas contra el paludismo
|
US8323664B2
(en)
|
2006-07-25 |
2012-12-04 |
The Secretary Of State For Defence |
Live vaccine strains of Francisella
|
DK2068918T3
(da)
|
2006-09-26 |
2012-07-30 |
Infectious Disease Res Inst |
Vaccinesammensætning omfattende syntetisk adjuvant
|
US20090181078A1
(en)
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
WO2008057396A2
(en)
|
2006-11-03 |
2008-05-15 |
Schering-Plough Ltd. |
Canine lyme disease vaccine
|
US20100055166A1
(en)
|
2007-03-02 |
2010-03-04 |
Gerald Hermann Voss |
Novel method and compositions
|
TW200908994A
(en)
|
2007-04-20 |
2009-03-01 |
Glaxosmithkline Biolog Sa |
Vaccine
|
WO2009000825A2
(en)
|
2007-06-26 |
2008-12-31 |
Glaxosmithkline Biologicals S.A. |
Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
|
EP2190470B1
(en)
|
2007-08-13 |
2017-12-13 |
GlaxoSmithKline Biologicals SA |
Vaccines
|
PT2227483T
(pt)
|
2007-12-19 |
2017-06-21 |
Henry M Jackson Found Advancement Military Medicine Inc |
Formas solúveis da glicoproteína f de vírus hendra e nipah e suas utilizações
|
WO2009143524A2
(en)
|
2008-05-23 |
2009-11-26 |
The Regents Of The University Of Michigan |
Nanoemulsion vaccines
|
GB0815872D0
(en)
|
2008-09-01 |
2008-10-08 |
Pasteur Institut |
Novel method and compositions
|
JP5722782B2
(ja)
|
2008-09-26 |
2015-05-27 |
ナノバイオ コーポレーション |
ナノエマルジョン治療用組成物及びその使用方法
|
GB0901411D0
(en)
|
2009-01-29 |
2009-03-11 |
Secr Defence |
Treatment
|
GB0901423D0
(en)
|
2009-01-29 |
2009-03-11 |
Secr Defence |
Treatment
|
EP3173097A3
(en)
|
2009-02-10 |
2017-07-12 |
Seqirus UK Limited |
Influenza vaccines with reduced amounts of squalene
|
GB0906234D0
(en)
|
2009-04-14 |
2009-05-20 |
Secr Defence |
Vaccine
|
US8668911B2
(en)
|
2009-05-14 |
2014-03-11 |
The Regents Of The University Of Michigan |
Streptococcus vaccine compositions and methods of using the same
|
EP2437753B1
(en)
|
2009-06-05 |
2016-08-31 |
Infectious Disease Research Institute |
Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them
|
CA2765511C
(en)
|
2009-06-16 |
2015-05-12 |
The Regents Of The University Of Michigan |
Nanoemulsion vaccines
|
GB0913680D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB0913681D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB0919117D0
(en)
|
2009-10-30 |
2009-12-16 |
Glaxosmithkline Biolog Sa |
Process
|
DE102009056883B4
(de)
*
|
2009-12-03 |
2012-08-16 |
Novartis Ag |
Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
|
EP2353609A1
(en)
|
2010-02-04 |
2011-08-10 |
Sanofi Pasteur |
Immunization compositions and methods
|
GB201003920D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Method of treatment
|
EP2552480A1
(en)
|
2010-03-26 |
2013-02-06 |
GlaxoSmithKline Biologicals S.A. |
Hiv vaccine
|
US8658603B2
(en)
|
2010-06-16 |
2014-02-25 |
The Regents Of The University Of Michigan |
Compositions and methods for inducing an immune response
|
AU2011310838B2
(en)
|
2010-09-27 |
2015-11-05 |
Crucell Holland B.V. |
Heterologous prime boost vaccination regimen against malaria
|
EA201390452A1
(ru)
|
2010-09-27 |
2013-11-29 |
Глаксосмитклайн Байолоджикалс С.А. |
Вакцина
|
CN103282375B
(zh)
|
2010-12-02 |
2017-01-11 |
比奥诺尔免疫有限公司 |
肽支架设计
|
GB201022007D0
(en)
|
2010-12-24 |
2011-02-02 |
Imp Innovations Ltd |
DNA-sensor
|
CA2821995C
(en)
|
2011-01-06 |
2019-02-12 |
Bionor Immuno As |
Monomeric and multimeric peptides immunogenic against hiv
|
US9044420B2
(en)
|
2011-04-08 |
2015-06-02 |
Immune Design Corp. |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
PT2758432T
(pt)
|
2011-09-16 |
2019-06-14 |
Ucb Biopharma Sprl |
Anticorpos neutralizantes contra as exotoxinas principais tcda e tcdb de clostridium difficile
|
WO2013074501A1
(en)
|
2011-11-14 |
2013-05-23 |
Crucell Holland B.V. |
Heterologous prime-boost immunization using measles virus-based vaccines
|
WO2013083753A2
(en)
|
2011-12-07 |
2013-06-13 |
Institut Pasteur |
Identification of a swine parecho-like virus and applications
|
LT2811981T
(lt)
|
2012-02-07 |
2019-06-10 |
Infectious Disease Research Institute |
Pagerintos adjuvanto kompozicijos, apimančios tlr4 agonistus, ir jų panaudojimo būdai
|
CN107540730B
(zh)
|
2012-05-16 |
2021-07-16 |
免疫设计公司 |
用于hsv-2的疫苗
|
EA201492262A1
(ru)
|
2012-06-06 |
2015-08-31 |
Бионор Иммуно Ас |
Конструкция пептидного каркаса
|
KR20200067938A
(ko)
|
2012-07-24 |
2020-06-12 |
사노피 파스퇴르 |
백신 조성물
|
MX2015000446A
(es)
|
2012-07-24 |
2015-03-12 |
Sanofi Pasteur |
Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue.
|
KR101819803B1
(ko)
|
2012-10-24 |
2018-01-17 |
플레이틀렛 타게티드 테라퓨틱스, 엘엘씨 |
혈소판 표적화 치료
|
WO2014083194A1
(en)
|
2012-11-30 |
2014-06-05 |
Sanofi Pasteur |
Methods for inducing antibodies
|
SG11201508092YA
(en)
|
2013-04-18 |
2015-10-29 |
Immune Design Corp |
Gla monotherapy for use in cancer treatment
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
US10208102B2
(en)
|
2013-11-01 |
2019-02-19 |
University Of Oslo |
Albumin variants and uses thereof
|
WO2015070207A2
(en)
|
2013-11-11 |
2015-05-14 |
The Government Of The United States, As Represented By The Secretary Of The Army |
Ama-1 epitopes, antibodies, compositions, and methods of making and using the same
|
CA2929126C
(en)
|
2013-11-13 |
2020-01-07 |
University Of Oslo |
Outer membrane vesicles and uses thereof
|
DK3069138T3
(en)
|
2013-11-15 |
2019-04-08 |
Univ Oslo Hf |
CTL PEPTID EPITOPES AND ANTIGEN-SPECIFIC T-CELLS, METHODS OF RECOGNITION THEREOF, AND APPLICATIONS THEREOF
|
WO2015077442A2
(en)
|
2013-11-20 |
2015-05-28 |
La Jolla Institute For Allergy And Immunology |
Grass pollen immunogens and methods and uses for immune response modulation
|
WO2015077434A2
(en)
|
2013-11-20 |
2015-05-28 |
La Jolla Institute For Allergy And Immunology |
Pan pollen immunogens and methods and uses for immune response modulation
|
WO2015092710A1
(en)
|
2013-12-19 |
2015-06-25 |
Glaxosmithkline Biologicals, S.A. |
Contralateral co-administration of vaccines
|
KR20220100041A
(ko)
|
2013-12-31 |
2022-07-14 |
인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) |
단일 바이알 백신 제형
|
EP3096764A1
(en)
|
2014-01-21 |
2016-11-30 |
Immune Design Corp. |
Compositions for use in the treatment of allergic conditions
|
WO2015131053A1
(en)
|
2014-02-28 |
2015-09-03 |
Alk-Abelló A/S |
Polypeptides derived from phl p and methods and uses thereof for immune response modulation
|
KR101696514B1
(ko)
*
|
2014-08-18 |
2017-01-24 |
서울대학교산학협력단 |
신규한 온도 민감성 마이코박테리아 균주 및 이를 포함하는 마이코박테리아 감염증에 대한 백신 조성물
|
EP3204039B1
(en)
|
2014-10-10 |
2022-06-08 |
The Regents Of The University Of Michigan |
Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
|
AR102547A1
(es)
|
2014-11-07 |
2017-03-08 |
Takeda Vaccines Inc |
Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
|
AU2015252119A1
(en)
|
2014-11-07 |
2016-05-26 |
Takeda Vaccines, Inc. |
Hand, foot, and mouth vaccines and methods of manufacture and use thereof
|
US10647964B2
(en)
|
2015-03-05 |
2020-05-12 |
Northwestern University |
Non-neuroinvasive viruses and uses thereof
|
GB201518684D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
WO2017158421A1
(en)
|
2016-03-14 |
2017-09-21 |
University Of Oslo |
Anti-viral engineered immunoglobulins
|
GEP20217232B
(en)
|
2016-03-14 |
2021-03-25 |
I Oslo Universitetet |
Engineered immunoglobulins with altered fcrn binding
|
WO2017201390A1
(en)
|
2016-05-19 |
2017-11-23 |
The Regents Of The University Of Michigan |
Novel adjuvant compositions
|
US11780924B2
(en)
|
2016-06-21 |
2023-10-10 |
University Of Oslo |
HLA binding vaccine moieties and uses thereof
|
BR112019003462A2
(pt)
|
2016-08-23 |
2019-06-25 |
Glaxosmithkline Biologicals Sa |
proteína de fusão, polinucleotídeo, vetor viral, composição farmacêutica, uso de uma proteína de fusão, polinucleotídeo, vetor viral ou composição farmacêutica, e, método para tratar ou prevenir infecção de hepatite b viral ou infecção de hepatite c viral
|
WO2018060288A1
(en)
|
2016-09-29 |
2018-04-05 |
Glaxosmithkline Biologicals S.A. |
Compositions and methods of treatment of persistent hpv infection
|
WO2018096396A1
(en)
|
2016-11-22 |
2018-05-31 |
University Of Oslo |
Albumin variants and uses thereof
|
GB201620968D0
(en)
|
2016-12-09 |
2017-01-25 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
SG11201911930SA
(en)
|
2017-06-11 |
2020-01-30 |
Molecular Express Inc |
Methods and compositions for substance use disorder vaccine formulations and uses thereof
|
CA3067224A1
(en)
|
2017-06-15 |
2018-12-20 |
Infectious Disease Research Institute |
Nanostructured lipid carriers and stable emulsions and uses thereof
|
EP3678698A1
(en)
|
2017-09-07 |
2020-07-15 |
University Of Oslo |
Vaccine molecules
|
WO2019048936A1
(en)
|
2017-09-07 |
2019-03-14 |
University Of Oslo |
VACCINE MOLECULES
|
KR20200085302A
(ko)
|
2017-11-03 |
2020-07-14 |
다케다 백신즈 인코포레이티드 |
지카 백신 및 면역원성 조성물 및 이의 사용 방법
|
GB201721068D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B immunisation regimen and compositions
|
GB201721069D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B Immunisation regimen and compositions
|
WO2019239311A1
(en)
|
2018-06-12 |
2019-12-19 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
CA3107077A1
(en)
|
2018-08-07 |
2020-02-13 |
Glaxosmithkline Biologicals Sa |
Processes and vaccines
|
EP3897846A1
(en)
|
2018-12-21 |
2021-10-27 |
GlaxoSmithKline Biologicals SA |
Methods of inducing an immune response
|
JP2022524007A
(ja)
|
2019-03-05 |
2022-04-27 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
B型肝炎免疫化レジメンおよび組成物
|
WO2020243115A1
(en)
|
2019-05-25 |
2020-12-03 |
Infectious Disease Research Institute |
Composition and method for spray drying an adjuvant vaccine emulsion
|
EP4103587A1
(en)
|
2020-02-14 |
2022-12-21 |
Immunor AS |
Corona virus vaccine
|
WO2024052882A1
(en)
|
2022-09-09 |
2024-03-14 |
Access To Advanced Health Institute |
Immunogenic vaccine composition incorporating a saponin
|